Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Medtech System ‘Too Rigorous’ For Innovation To Flourish, Argues Healthtech Expert

Executive Summary

David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.

You may also be interested in...



Bernasconi: Europe Needs A Better Strategic Rudder For Medtech Innovation Policy

Always ready to frame the needs of EU medtechs clearly and succinctly, MedTech Europe CEO Serge Bernasconi says that the local industry in the future could benefit from more strategic direction and support from a dedicated EU agency or similar tighter governance structure.

Start-Up Spotlight: CorWave Takes Inspiration From Nature To Tackle Heart Failure

Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.

Kalvista Stops Phase II HAE Prophylactic Trial Following Liver Enzyme Concerns

The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel